ChromaDex Looks To Pharma Model For Commercializing Supplement Research
This article was originally published in The Tan Sheet
Executive Summary
Nutritional ingredient developer ChromaDex is employing a pharma-style business model to expand its R&D into finished dietary supplements – with a long-term eye on pharmaceutical products. The firm’s recent hire of CEO Jeffrey Himmel was a significant step into the consumer products arena.
You may also be interested in...
People In Brief
Himmel named ChromaDex CEO; Pinney reorganizes senior management; FDA vet Chappell jumps to Greenleaf; more People In Brief.
Glaxo Shifts Rx Resveratrol Focus But Nutritional Interest Still Strong
GlaxoSmithKline's decision to abandon its pharmaceutical research program on resveratrol leaves the red wine extract exclusively to the nutritionals industry.
Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?
Omega-3 fish oils, once exclusive to the realm of dietary supplements, increasingly are swimming upstream into prescription drugs – a trend with both positive and negative implications for supplements.